DOCSLIB.ORG

Chadi Abdallah, M.D. Associate Member Yale University Ted Abel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chadi Abdallah, M.D. Associate Member Yale University Ted Abel Chadi Abdallah, M.D. Ted Abel, Ph.D. James Abelson, M.D., Ph.D Associate Member Fellow Member Emeritus Yale University University of Iowa University of Michigan Elizabeth Abercrombie, Ph.D. Anissa Abi-Dargham, M.D. Megumi Adachi, Ph.D. Fellow Fellow Associate Member Rutgers University Stony Brook University Astellas Research Institute R. Alison Adcock, M.D., Ph.D Nika Adham, B.Sc., M.Sc., Ph.D. Bryon Adinoff, M.D. Associate Member Member Fellow Emeritus Duke University Allergan, Inc. University of Colorado Caleb Adler, M.D. Martin Adler, Ph.D. George Aghajanian, M.D. Member Fellow Emeritus Fellow Emeritus University of Cincinnati Temple University Yale University Bernard Agranoff, B.S., M.D. Susanne Ahmari, M.D., Ph.D Katherine Aitchison, FRCPsy, Prof. Dr. Fellow Emeritus Member med University of Michigan University of Pittsburgh Member University of Alberta Howard Aizenstein, M.D., Ph.D Olusola Ajilore, M.D., Ph.D Schahram Akbarian, M.D., Ph.D Member Member Member University of Pittsburgh University of Illinois at Chicago Icahn School of Medicine At Mount Sinai Huda Akil, Ph.D. Martin Alda, FRCPC, M.D. Robert Alexander, M.D. Fellow Member Member University of Michigan Dalhousie University Takeda George Alexopoulos, M.D. Tanya Alim, M.D. Murray Alpert, Ph.D. Fellow Emeritus Member Fellow Emeritus Weill Cornell Medical College Howard University Larry Alphs, M.D., Ph.D C. Anthony Altar, Ph.D. Susan Amara, Ph.D. Member Member Emeritus Fellow Newron Pharmaceuticals Verge Genomics, Inc National Institute of Mental Health Stephanie Ameis, FRCP(C), M.D., M.Sc. Susan Andersen, Ph.D. Nancy Andreasen, M.D., Ph.D Associate Member Fellow Fellow Centre for Addiction and Mental Health McLean Hospital University of Iowa Ana Andreazza, Ph.D. Anne Andrews, Ph.D. Burt Angrist, M.D., Med Associate Member Fellow Fellow Emeritus University of Toronto University of California, Los Angeles The New York University Jules Angst, Prof. Dr. med Mark Ansorge, Ph.D. James Anthony, Ph.D., Prof. Fellow Emeritus Associate Member Fellow Emeritus University of Zurich Columbia University Michigan State University Raymond Anton, M.D. James Appel, Ph.D. Paul Appelbaum, M.D. Fellow Emeritus Fellow Emeritus Fellow Medical University of South Carolina University of South Carolina Columbia University Victoria Arango, B.S., Ph.D. Albert Arias, M.D., M.S. Steven Arnold, M.D. Fellow Emeritus Associate Member Member NIMH Virginia Commonwealth University Harvard Medical School Francesc Artigas, Prof. Dr. Robert Asarnow, Ph.D. Marie Asberg, M.D., Ph.D Fellow Member Fellow Emeritus Instituto de Investigaciones Biomédicas University of California, Los Angeles Karolinska Institutet de Barcelona Rebecca Ashare, Ph.D. Gary Aston-Jones, Ph.D. Nancy Ator, B.A., M.S., Ph.D. Associate Member Fellow Member Emeritus University of Pennsylvania Rutgers University Johns Hopkins School of Medicine Efrain Azmitia, Ph.D. Ryan Bachtell, Ph.D. Ursula Bailer, M.D., Prof. Dr. med Fellow Emeritus Associate Member Fellow New York University University of Colorado University of California, San Diego David Baker, Ph.D. Vaishali Bakshi, Ph.D. Ross Baldessarini, M.D., Sc.D. Member Fellow Fellow Emeritus Marquette University University of Wisconsin Harvard Medical School Tracy Bale, Ph.D. James Ballenger, M.D. Robert Balster, Ph.D. Member Fellow Emeritus Fellow Emeritus University of Maryland Virginia Commonwealth University Darrick Balu, Ph.D. Thomas Ban, FRCP(C), M.D. Debra Bangasser, Ph.D. Associate Member Fellow Emeritus Associate Member Harvard Medical School Temple University Matthew Banks, Ph.D., Pharm.D. Jay Baraban, M.D., Ph.D Tallie Z. Baram, M.D., Ph.D Associate Member Member Emeritus Member Virginia Commonwealth University Johns Hopkins University University of California, Irvine Deanna Barch, Ph.D. Jack Barchas, M.D. Samuel Barondes, M.D. Fellow Fellow Fellow Emeritus Washington University Weill Cornell Medical College University of California, San Francisco Christina Barr, Ph.D. James Barrett, Ph.D. Herbert Barry, Ph.D. Fellow Fellow Emeritus Member Emeritus NIAAA Drexel University College of Medicine University of Pittsburgh Raymond Bartus, Ph.D. Lewis Baxter, M.D. Carrie Bearden, Ph.D. Fellow Emeritus Fellow Emeritus Fellow RTBioconsultants, Inc. Self-Employed University of California at Los Angeles Charles Beasley, M.D. Jean-Martin Beaulieu, Ph.D. Sheryl Beck, B.S., M.S., Ph.D. Fellow Emeritus Member Fellow Emeritus Beasley Pharmaceutical and University of Toronto University of Pennsylvania Biotechnology Consulting, LLC Howard Becker, Ph.D. Jill Becker, Ph.D. Aysenil Belger, Ph.D. Member Fellow Member Medical University of South Carolina University of Michigan University of North Carolina at Chapel Hill Alan Bellack, Ph.D. Robert Belmaker, M.D. Ruth Benca, M.D., Ph.D Fellow Emeritus Fellow Emeritus Fellow University of Maryland Ben Gurion University University of California, Irvine Francine Benes, M.D., Ph.D Helene Benveniste, M.D., Ph.D Jack Bergman, Ph.D. Fellow Emeritus Member Member Emeritus McLean Hospital Yale School of Medicine McLean Hospital Karen Berman, M.D. Sabina Berretta, M.D. Wade Berrettini, M.D., Ph.D Fellow Fellow Fellow Emeritus National Institutes of Health McLean Hospital University of Pennsylvania Alessandro Bertolino, M.D., Ph.D Cynthia Bethea, Ph.D. Zubin Bhagwagar, D.Phil., M.D. Member Fellow Emeritus Fellow University of Bari Oregon National Primate Research Alexion Pharmaceuticals Center Anindya Bhattacharya, Ph.D. Giovanni Biggio, Ph.D., Prof. Kristin Bigos, Ph.D. Member Fellow Associate Member Janssen Research & Development, LLC University of Cagliari Johns Hopkins School of Medicine Staci Bilbo, Ph.D. Robert Bilder, Ph.D. Elisabeth Binder, M.D., Ph.D Member Fellow Member Harvard Medical School Semel Institute Emory University School of Medicine Garth Bissette, Ph.D. Thomas Blackburn, D.Sc., Ph.D. Jennifer Blackford, Ph.D. Fellow Emeritus Member Emeritus Member Retired TPBioVentures Ltd. Vanderbilt University Medical Center Barry Blackwell, M.D. Randy Blakely, Ph.D. Carlos Blanco, M.D., Ph.D Fellow Emeritus Fellow Fellow Florida Atlantic University National Institute on Drug Abuse Dan Blazer, M.D., M.P.H., Ph.D. David Bleakman, Ph.D. Pierre Blier, M.D., Ph.D Member Emeritus Member Fellow Duke University University of Bristol University of Ottawa Michael Bloch, M.D., M.S. Floyd Bloom, M.D. Hilary Blumberg, M.D. Member Fellow Emeritus Member Yale Child Study Center The Scripps Research Institute Yale University School of Medicine Laura Bohn, Ph.D. Isabelle Boileau, Ph.D. Carlos Bolanos-Guzman, Ph.D. Fellow Associate Member Fellow The Scripps Research Institute Centre for Addiction and Mental Health Texas A&M University Maura Boldrini, M.D., Ph.D Pascal Bonaventure, Ph.D. Antonello Bonci, M.D., Ph.D Member Member Fellow Columbia University Janssen Research & Development, LLC NIDA Alexander Borbely, M.D. Stephanie Borgland, Ph.D. Charles Bowden, M.D. Fellow Emeritus Associate Member Fellow Emeritus University of Zurich University of Calgary The University of Texas Health Science Center At San Antonio Charles Bradberry, Ph.D. Kathleen Brady, M.D., Ph.D Linda Brady, Ph.D. Fellow Fellow Fellow NIDA Medical University of South Carolina National Institute of Mental Health David Braff, M.D. Theresa Branchek, Ph.D. Nicholas Brandon, M.A., Ph.D. Fellow Emeritus Fellow Emeritus Fellow University of California, San Diego Sub Arbore Consulting AstraZeneca Stephen Brannan, M.D. David Bredt, M.D., Ph.D George Breese, Ph.D. Member Member Fellow Emeritus Karuna Pharmaceuticals Janssen University of Northa Carolina Alan Breier, M.D. John Breitner, M.D., M.P.H. J. Douglas Bremner, M.D. Fellow Emeritus Fellow Emeritus Member Indiana University McGill University Emory University Heather Brenhouse, Ph.D. Kristen Brennand, Ph.D. David Brent, M.D., M.S. Associate Member Associate Member Member Emeritus Northeastern University Icahn School of Medicine at Mount Western Psychiatric Institute & Clinic Sinai Lisa Briand, Ph.D. Jennifer Britton, Ph.D. Arthur Brody, M.D. Associate Member Associate Member Fellow Temple University University of Miami University of California, San Diego Melissa Brotman, Ph.D. Alan Brown, M.D., M.P.H. E. Sherwood Brown, M.D., Ph.D Member Fellow Fellow National Institute of Mental Health Columbia University University of Texas Lawrence Brown, B.A., M.D., M.P.H. Walter Brown, M.D. Michael Bruchas, Ph.D. Fellow Emeritus Fellow Emeritus Member START Treatment and Recovery Centers Brown University Washington University John Bruno, Ph.D. Camron Bryant, Ph.D. Maja Bucan, Ph.D. Fellow Associate Member Member Ohio State University Boston University University of Pennsylvania Robert Buchanan, M.D. Monte Buchsbaum, M.D. Benjamin Bunney, M.D. Fellow Fellow Fellow Emeritus University of Maryland University of California, San Diego Yale University William Bunney, M.D. Katherine Burdick, Ph.D. Jeffrey Burgdorf, Ph.D. Fellow Emeritus Fellow Associate Member University of California, Irvine Harvard Medical School Northwestern University Margit Burmeister, Ph.D. Juan Bustillo, M.D. Joseph Buxbaum, Ph.D. Fellow Member Fellow University of Michigan University of New Mexico Icahn School of Medicine at Mount Sinai William Byerley, M.D. Frank Bymaster, M.S. Ricardo Caceda, M.D., Ph.D Member Member Associate Member University of California, San Francisco TRImaran Pharma, Inc. Stony Brook University Kristin Cadenhead, M.D. Denise Cai, Ph.D. Joseph Calabrese, M.D. Fellow Associate Member Fellow University of California, San Diego Icahn School of Medicine at Mount Case Western Reserve University Sinai Vince Calhoun, M.A., M.S., Ph.D. Erin Calipari, Ph.D. Joseph Callicott, M.D. Fellow Associate Member Fellow The Mind Research Network Vanderbilt University NIMH Judy Cameron, Ph.D. Magda Campbell, M.D. Joan Camprodon, M.D., M.P.H., Ph.D. Member Fellow Emeritus Associate Member University of Pittsburgh New York University Harvard Medical School Jose Canive, FRCP(C), M.D. William Carlezon, Ph.D. Marc Caron, Ph.D. Fellow Fellow Member Emeritus University of New Mexico Harvard Medical School Duke University Linda Carpenter, M.D.
Load more

Recommended publications
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Serotonin Model of Schizophrenia: Emerging Role of Glutamate Mechanisms 1
    Brain Research Reviews 31Ž. 2000 302±312 www.elsevier.comrlocaterbres Interactive report Serotonin model of schizophrenia: emerging role of glutamate mechanisms 1 George K. Aghajanian ), Gerard J. Marek Departments of Psychiatry and Pharmacology, Yale UniÕersity School of Medicine and the Connecticut Mental Health Center, 34 Park St., New HaÕen, CT 06508, USA Accepted 30 June 1999 Abstract The serotoninŽ. 5-HT hypothesis of schizophrenia arose from early studies on interactions between the hallucinogenic drug LSD Ž.D-lysergic acid diethylamide and 5-HT in peripheral systems. More recent studies have shown that the two major classes of psychedelic hallucinogens, the indoleaminesŽ. e.g., LSD and phenethylamines Ž e.g., mescaline . , produce their central effects through a common action upon 5-HT2 receptors. This review focuses on two brain regions, the locus coeruleus and the cerebral cortex, where the actions of indoleamine and the phenethylamine hallucinogens have been shown to be mediated by 5-HT2A receptors; in each case, the hallucinogens Ž.via 5-HT2A receptors have been found to enhance glutamatergic transmission. In the prefrontal cortex, 5-HT2A -receptors stimulation increases the release of glutamate, as indicated by a marked increase in the frequency of excitatory postsynaptic potentialsrcurrents Ž.EPSPsrEPSCs in the apical dendritic region of layer V pyramidal cells; this effect is blocked by inhibitory group IIrIII metabotropic glutamate agonists acting presynaptically and by an AMPArkainate glutamate antagonist, acting postsynaptically at non-NMDA glutamate receptors. A major alternative drug model of schizophrenia, previously believed to be entirely distinct from that of the psychedelic hallucinogens, is based on the psychotomimetic properties of antagonists of the NMDA subtype of glutamate receptorŽ e.g., phencylidine and ketamine.
    [Show full text]
  • Ketamine Psychedelic Psychotherapy: Focus on Its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Private Practice
    International Journal of Transpersonal Studies Volume 33 | Issue 2 Article 8 7-1-2014 Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Private Practice Harris L. Friedman University of Florida Evgeny Krupitsky St. Petersburg State Pavlov Medical University Karl Jansen Auckland Hospital Mark Sylvester Private Practice See next page for additional authors Follow this and additional works at: https://digitalcommons.ciis.edu/ijts-transpersonalstudies Part of the Philosophy Commons, Psychiatry and Psychology Commons, and the Religion Commons Recommended Citation Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Kolp, E., Friedman, H. L., Krupitsky, E., Jansen, K., Sylvester, M., Young, M. S., & Kolp, A. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84–140.. International Journal of Transpersonal Studies, 33 (2). http://dx.doi.org/10.24972/ijts.2014.33.2.84 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This Special Topic Article is brought to you for free and open access by the Journals and Newsletters at Digital Commons @ CIIS. It has been accepted for inclusion in International Journal of Transpersonal Studies by an authorized administrator of Digital Commons @ CIIS. For more information, please contact [email protected]. Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Authors Eli Kolp, Harris L. Friedman, Evgeny Krupitsky, Karl Jansen, Mark Sylvester, M. Scott ounY g, and Anna Kolp This special topic article is available in International Journal of Transpersonal Studies: https://digitalcommons.ciis.edu/ijts- transpersonalstudies/vol33/iss2/8 Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications Eli Kolp Harris L.
    [Show full text]
  • Chadi Abdallah, M.D. Associate Member Baylor College of Medicine
    Chadi Abdallah, M.D. Ted Abel, Ph.D. James Abelson, M.D.,Ph.D. Associate Member Fellow Member Emeritus Baylor College of Medicine University of Iowa, Carver College of University of Michigan Health System Medicine Anissa Abi-Dargham, M.D. Megumi Adachi, Ph.D. R. Alison Adcock, M.D.,Ph.D. Fellow Associate Member Associate Member Stony Brook University Astellas Research Institute of America Duke University LLC Nii Addy, Ph.D. Nika Adham, B.Sc.,M.Sc.,Ph.D. Bryon Adinoff, M.D. Associate Member Member Fellow Emeritus Yale University School of Medicine Abbvie University of Colorado Medical School Caleb Adler, M.D. Martin Adler, Ph.D. George Aghajanian, M.D. Member Fellow Emeritus Fellow Emeritus University of Cincinnati College of Temple University School of Medicine Yale University School of Medicine Medicine Bernard Agranoff, B.S.,M.D. Susanne Ahmari, M.D.,Ph.D. Katherine Aitchison, Fellow Emeritus Member B.A.,FRCPsych,Ph.D. University of Michigan University of Pittsburgh Member University of Alberta Howard Aizenstein, M.D.,Ph.D. Olusola Ajilore, M.D.,Ph.D. Schahram Akbarian, M.D.,Ph.D. Member Member Member University of Pittsburgh University of Illinois at Chicago Icahn School of Medicine At Mount Sinai Huda Akil, Ph.D. Martin Alda, FRCPC,M.D. Robert Alexander, M.D. Fellow Member Member University of Michigan Dalhousie University Takeda George Alexopoulos, M.D. Tanya Alim, M.D. Murray Alpert, Ph.D. Fellow Emeritus Member Fellow Emeritus Weill Cornell Medical College Howard University Larry Alphs, M.D.,Ph.D. C. Anthony Altar, Ph.D. Susan Amara, Ph.D.
    [Show full text]
  • AN ORAL HISTORY of NEUROPSYCHOPHARMACOLOGY the FIRST FIFTY YEARS Peer Interviews
    AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Volume Two: Neurophysiology Copyright © 2011 ACNP Thomas A. Ban (series editor) AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY Max Fink (volume editor) VOLUME 2: Neurophysiology All rights reserved. No part of this book may be used or reproduced in any manner without written permission from the American College of Neuropsychopharmacology (ACNP). Library of Congress Cataloging-in-Publication Data Thomas A. Ban, Max Fink (eds): An Oral History of Neuropsychopharmacology: The First Fifty Years, Peer Interviews Includes bibliographical references and index ISBN: 1461161452 ISBN-13: 9781461161455 1. Electroencephalography and neurophysiology 2. Pharmaco-EEG 3. Sleep EEG 4. Cerebral blood flow 5. Brain metabolism 6. Brain imaging Publisher: ACNP ACNP Executive Office 5034A Thoroughbred Lane Brentwood, Tennessee 37027 U.S.A. Email: [email protected] Website: www.acnp.org Cover design by Jessie Blackwell; JBlackwell Design www.jblackwelldesign.com AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY AN ORAL HISTORY OF NEUROPSYCHOPHARMACOLOGY THE FIRST FIFTY YEARS Peer Interviews Edited by Thomas A. Ban Co-editors Volume 1: Starting Up - Edward Shorter Volume 2: Neurophysiology - Max Fink Volume 3: Neuropharmacology - Fridolin Sulser Volume 4: Psychopharmacology - Jerome Levine Volume 5: Neuropsychopharmacology - Samuel Gershon Volume 6: Addiction - Herbert D. Kleber Volume 7: Special Areas - Barry Blackwell Volume 8: Diverse Topics - Carl Salzman Volume 9: Update - Barry Blackwell Volume 10: History of the ACNP - Martin M. Katz VOLUME 2 NEUROPHYSIOLOGY ACNP 2011 VOLUME 2 Max Fink NEUROPHYSIOLOGY Preface Thomas A. Ban Dedicated to the Memory of Jonathan O. Cole, President ACNP, 1966 PREFACE Thomas A. Ban In Volume 1 of this series, 22 clinicians and basic scientists reflected on their contributions to the “starting up” of neuropsychopharmacology (NPP).
    [Show full text]
  • Tuesday, December 14 Poster Session II
    Neuropsychopharmacology (2004) 29, S127-S182 © 2004 Nature Publishing Group All rights reserved 0893-133X/04 www.neuropsychopharmacology.org S127 Tuesday, December 14 that does not activate ganglion or muscle-type nicotinic acetylcholine Poster Session II - Tuesday receptors. It is orally active, has shown long lasting cognitive effects in animal models and neuroprotective effects in vitro. Methods: Four early placebo-controlled studies in humans have been completed and 1. Effect of Memantine on Behavioral Outcomes in Moderate to partial data from a fifth are available (N=124). The completed stud- Severe Alzheimer’s Disease ies include SRD, MRD, food interaction and a PK in the elderly. Sin- Jeffrey L Cummings*,Eugene Schneider, Pierre N Tariot and gle doses up to 320mg and multiple doses for 10 days up to 200mg, Stephen M Graham have been explored. An ongoing study in elderly subjects with age as- Department of Neurology, University of California Los Angeles, Los sociated memory impairment (AAMI) involves three-week dosing up Angeles, CA, USA to 150mg. Safety/Tolerability: The drug was well tolerated overall. No changes of clinical significance were detected on biochemistry Memantine is a low-moderate affinity, uncompetitive N- testing, urine analysis, vital signs, ECG or 24-hour Holter monitor- methyl-D-aspartate (NMDA) receptor antagonist approved for the ing. Adverse events (AEs) were mild to moderate in intensity. Severe treatment of moderate to severe Alzheimer’s disease (AD). Excitotox- AEs were only seen at MTD - identifed in these studies as 320mg in icity mediated by NMDA receptors is thought to play a role in the the young and 150mg in the elderly.
    [Show full text]
  • Noradrenergic Regulation of Serotonergic Neurons in the Dorsal Raphe : Physiological, Pharmacological, and Anatomical Studies Jay Matthew Ab Raban Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1980 Noradrenergic regulation of serotonergic neurons in the dorsal raphe : physiological, pharmacological, and anatomical studies Jay Matthew aB raban Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Baraban, Jay Matthew, "Noradrenergic regulation of serotonergic neurons in the dorsal raphe : physiological, pharmacological, and anatomical studies" (1980). Yale Medicine Thesis Digital Library. 2374. http://elischolar.library.yale.edu/ymtdl/2374 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/noradrenergicregOObara ABSTRACT NORADRENERGIC REGULATION OF SEROTONERGIC NEURONS IN THE DORSAL RAPHE: PHYSIOLOGICAL, PHARMACOLOGICAL AND ANATOMICAL STUDIES Jay Matthew Baraban Yale University 1980 Recent pharmacological studies suggest that a central nor¬ adrenergic (NE) system regulates the firing activity of the serotonin (5-HT)-containing neurons in the dorsal raphe nucleus. Reduction of noradrenergic tone by a variety of pharmacological interventions leads to a suppression of 5-HT cell firing (Svensson et al., 1975). It has been suggested that an alpha-adrenoceptor mediates NE's effects since systemic administration of an alpha-adrenoceptor antagonist, piperoxan, reduces 5-HT cell firing (Gallager and Aghajanian, 1976a).
    [Show full text]
  • Feeling Good Mental Health and Its Opposite
    Feeling good Mental health and its opposite Spring 2019 ALSO 4 New stem-cell extraction procedure / 7 The transformation of the Medical Library / 42 Long career of service Features 12/ Rethinking mental illness A look at the state of mental health and its inverse, mental illness, from Yale School of Medicine faculty and researchers from the departments of psychiatry and neuroscience. By Steve Hamm 18/ Breaking the cycle of traumatic memories Trials offering ketamine doses to patients suffering from post-traumatic stress disorder give some veterans hope that they can live a normal life. By Courtney McCarroll 22/ Taking psychiatric help to the street Emma Lo, MD, a fourth-year resident in Yale School of Medicine’s psychiatry program, spearheads a street psychiatry team many hope will help manage Connecticut’s part of the national substance use disorder epidemic. By Steve Hamm 24/ Brain bank aids theories on genetics and post-traumatic stress disorder Yale School of Medicine researchers use a massive brain-tissue repository, or “brain bank,” at the VA’s National Center for PTSD to postulate generalizations about the genetic origins of the condition and its physiological characteristics. By Jenny Blair, MD ’04 28/ Computational psychiatry: Modeling the brain’s neural circuitry Alan Anticevic, PhD, and John Murray, PhD, have combined efforts in order to under- stand the biology that underpins the brain’s neural system. By Katherine L. Kraines 30/ Why concussions hurt some people more than others Researchers are examining the relationship between concussions and depression in the hope of understanding why some people develop more extreme symptoms than others.
    [Show full text]
  • DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons
    The Journal of Neuroscience, December 1, 2000, 20(23):8846–8852 DOI-Induced Activation of the Cortex: Dependence on 5-HT2A Heteroceptors on Thalamocortical Glutamatergic Neurons Jennifer L. Scruggs,* Sachin Patel,* Michael Bubser, and Ariel Y. Deutch Departments of Psychiatry and Pharmacology and Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, Tennessee 37212 Administration of the hallucinogenic 5-HT2A/2C agonist 1-[2,5- band of Fos immunoreactive neurons was in register with antero- dimethoxy-4-iodophenyl]-2-aminopropane (DOI) induces ex- gradely labeled axons from the ventrobasal thalamus, which pression of Fos protein in the cerebral cortex. To understand the have previously been shown to be glutamatergic and express the mechanisms subserving this action of DOI, we examined the 5-HT2A transcript. The effects of DOI were markedly reduced in consequences of pharmacological and surgical manipulations on animals pretreated with the AMPA/KA antagonist GYKI 52466, DOI-elicited Fos expression in the somatosensory cortex of the and lesions of the ventrobasal thalamus attenuated DOI-elicited rat. DOI dose-dependently increased cortical Fos expression. Fos expression in the cortex. These data suggest that DOI Pretreatment with the selective 5-HT2A antagonist MDL 100,907 activates 5-HT2A receptors on thalamocortical neurons and completely blocked DOI-elicited Fos expression, but pretreat- thereby increases glutamate release, which in turn drives Fos ment with the 5-HT2C antagonist SB 206,553 did not modify expression in cortical neurons through an AMPA receptor- DOI-elicited Fos expression. These data suggest that DOI acts dependent mechanism. These data cast new light on the mech- through 5-HT2A receptors to increase cortical Fos expression.
    [Show full text]
  • Serotonin, Via 5-HT Receptors, Increases Epscs in Layer V
    Brain Research 825Ž. 1999 161±171 Research report Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release George K. Aghajanian ), Gerard J. Marek Departments of Psychiatry and Pharmacology, Yale School of Medicine, Yale UniÕersity, New HaÕen, CT 06508, USA Connecticut Mental Health Center, 34 Park St., New HaÕen, CT 06508, USA Accepted 9 February 1999 Abstract Previously, serotoninŽ. 5-HT was found to induce a marked increase in glutamatergic spontaneous excitatory postsynaptic currents Ž.EPSCs in apical dendrites of layer V pyramidal cells of prefrontal cortex; this effect was mediated by 5-HT2A receptors, a proposed site of action of hallucinogenic and atypical antipsychotic drugs. Unexpectedly, although the effect of 5-HT was Ca2q-dependent and tetrodotoxin-sensitive, it did not appear to involve the activation of excitatory afferent impulse flow. This paradox prompted us to investigateŽ. in rat brain slices whether 5-HT was acting through an atypical mode of excitatory transmitter release. We found that the frequency of 5-HT-induced spontaneous EPSCs was fully supported by Sr 2q in the absence of added Ca2q, implicating the mechanism of asynchronous transmitter release which has been linked to the high-affinity Ca2q-sensor synaptotagmin III. Although the early, synchronous component of electrically eÕoked EPSCs was reduced while 5-HT was being applied, late, nonsynchronous components were enhanced during 5-HT washout and also by the 5-HT2 partial agonist 1-ŽŽ. 2,5-dimethoxy-4-iodophenyl-2-aminopropane DOI ; the effect of DOI was blocked by a selective 5-HT2A antagonistŽ.
    [Show full text]
  • Hallucinogens
    Pharmacology & Therapeutics 101 (2004) 131–181 www.elsevier.com/locate/pharmthera Associate editor: B.L. Roth Hallucinogens David E. Nichols* Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907-2091, USA Abstract Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain. These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, especially those expressed on neocortical pyramidal cells. Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents. These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC). In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metabolism, and correlations have been developed between activity in specific brain areas and psychological elements of the ASC produced by hallucinogens.
    [Show full text]
  • A Career in Biological Psychiatry
    A CAREER IN BIOLOGICAL PSYCHIATRY HERBERT MELTZER Why did you go into medicine Why did I go into medicine? I came from a family of very bright people but who didn't have the opportunity for higher education. The first really educated person who came into my life was the general practitioner, who treated my family. He was someone I esteemed greatly. I had a couple of serious illnesses when I was a kid. Once I got rather extensive second degree burns, which he helped me survive. I was thought to have a heart murmur, which probably was not the case. Nevertheless, it led to a certain amount of contact with doctors and a genuine respect for the profession. As I grew older and took science courses in high school, I started to think of myself as potentially going into medicine. I registered as a pre-medical student when I began college at Cornell University in 1954. I was also very interested in philosophy at the time and as one could go into medicine in the States without a science degree, I continued to take the more introductory level science courses offered for pre-medical students, along with philosophy. I took the Pre-med organic chemistry course at the same time as I was taking a course in logical positivist philosophy, which was the dominent approach to philosophy in the United States at that time. I found this type of philosophy very arid and stultifying, while the organic chemistry was brilliantly taught and very exciting. I perceived the opportunities it provided for creativity and for synthesizing general principles; the mastery that seemed possible completely engaged me.
    [Show full text]